University of Michigan Department of Internal Medicine, Frankel Cardiovascular Center, Rush Medical College, Rush University Medical Center, Ann Arbor, Michigan, USA.
University of Michigan Department of Internal Medicine, Frankel Cardiovascular Center, Ann Arbor, Michigan, USA.
J Thromb Haemost. 2022 Nov;20(11):2571-2578. doi: 10.1111/jth.15850. Epub 2022 Sep 1.
Differences in clinical outcomes following a temporary interruption of warfarin or a direct oral anticoagulant (DOAC) for a surgical procedure are not well described. Differences in patient characteristics from practice-based cohorts have not typically been accounted for in prior analyses.
To describe risk-adjusted differences in postoperative outcomes following an interruption of warfarin vs DOACs.
Patients receiving care at six anticoagulation clinics participating in the Michigan Anticoagulation Quality Improvement Initiative were included if they had at least one oral anticoagulant interruption for a procedure. Inverse probability of treatment weighting (IPTW) was used to balance baseline differences between the warfarin cohort and DOAC cohort. Bleeding and thromboembolic events within 30 days following the procedure were compared between the IPTW cohorts using the Poisson distribution test.
A total of 525 DOAC patients were matched with 1323 warfarin patients, of which 923 were nonbridged warfarin patients and 400 were bridged warfarin patients. The occurrence of postoperative minor bleeding (10.8% vs. 4.7%, p < .001), major bleeding (2.9% vs. 1.1%, p = .01) and clinically relevant nonmajor bleeding (CRNMB) (6.5% vs. 3.0%, p = .002) was greater in the DOAC cohort compared with the nonbridged warfarin cohort. The rates of postoperative bleeding outcomes were similar between the DOAC and the bridged warfarin cohorts.
Perioperative interruption of DOACs, compared with warfarin without bridging, is associated with a higher incidence of 30-day minor bleeds, major bleeds, and CRNMBs. Further research investigating the perioperative outcomes of these two classes of anticoagulants is warranted.
对于手术期间暂时中断华法林或直接口服抗凝剂(DOAC)的患者,其临床结局的差异尚未得到很好的描述。在之前的分析中,通常没有考虑到来自实践队列的患者特征差异。
描述华法林与 DOAC 中断后术后结局的风险调整差异。
如果至少有一次口服抗凝剂中断用于手术,参加密歇根州抗凝质量改进计划的六个抗凝诊所的患者将被纳入研究。使用逆概率治疗加权(IPTW)来平衡华法林队列和 DOAC 队列之间的基线差异。使用泊松分布检验比较术后 30 天内的出血和血栓栓塞事件。
共有 525 名 DOAC 患者与 1323 名华法林患者相匹配,其中 923 名是非桥接华法林患者,400 名是桥接华法林患者。与非桥接华法林队列相比,DOAC 队列术后发生轻微出血(10.8% vs. 4.7%,p<0.001)、大出血(2.9% vs. 1.1%,p=0.01)和临床相关非大出血(CRNMB)(6.5% vs. 3.0%,p=0.002)的发生率更高。DOAC 队列和桥接华法林队列的术后出血结局发生率相似。
与无桥接的华法林相比,DOAC 的围手术期中断与 30 天内轻微出血、大出血和 CRNMB 的发生率更高。需要进一步研究这两种抗凝剂的围手术期结局。